VeraBank N.A. Acquires Shares of 22,439 Kenvue Inc. $KVUE

VeraBank N.A. bought a new position in Kenvue Inc. (NYSE:KVUE) during the second quarter, Holdings Channel reports. The firm bought 22,439 shares of the company’s stock, valued at approximately $470,000.

Several other institutional investors have also added to or reduced their stakes in the company. Pittenger & Anderson Inc. purchased a new stake in shares of Kenvue during the 1st quarter worth approximately $30,000. Trust Co. of Vermont lifted its position in Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after purchasing an additional 1,150 shares during the last quarter. TruNorth Capital Management LLC purchased a new position in shares of Kenvue in the 1st quarter worth $36,000. Truvestments Capital LLC purchased a new position in shares of Kenvue in the 1st quarter worth $37,000. Finally, Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after buying an additional 1,287 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

KVUE has been the subject of several recent research reports. Citigroup dropped their price target on Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, October 9th. UBS Group dropped their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, October 8th. Johnson Rice restated a “neutral” rating on shares of Kenvue in a research report on Tuesday, October 28th. Rothschild Redb upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 26th. Finally, Deutsche Bank Aktiengesellschaft set a $18.00 target price on shares of Kenvue in a report on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $20.23.

Kenvue Price Performance

NYSE KVUE opened at $16.79 on Tuesday. The company has a market cap of $32.17 billion, a PE ratio of 22.39, a P/E/G ratio of 2.46 and a beta of 0.71. The firm’s 50 day moving average price is $16.69 and its 200-day moving average price is $20.22. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE) last announced its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.83 billion. During the same quarter last year, the firm earned $0.28 EPS. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th will be given a $0.2075 dividend. The ex-dividend date of this dividend is Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.9%. Kenvue’s payout ratio is presently 110.67%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.